Loading...
At this year's annual meeting of the American Society of Clinical Oncology (ASCO 2015), held May 29 through June 2 in Chicago, specialists discussed the latest findings in cancer research. The editors of NEJM Journal Watch Oncology and Hematology were in attendance to report highlights of the conference. Here, Associate Editor Michael Williams, MD, ScM, reviews key presentations on new treatments for hematologic malignancies. All meeting abstracts can be viewed in the ASCO meeting library.
Elotuzumab is a humanized monoclonal antibody that targets the surface protein SLAMF7 (CS1) on virtually all myeloma tumor cells, independent of cytogenetic subtype. Lonial and colleagues conducted a ph…